![Filip Janku](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Filip Janku
Teknisk/Vetenskaplig/F&U Direktör på
MONTE ROSA THERAPEUTICS, INC.
Förmögenhet: 1 M $ per 2026-06-30
Profil
Filip Janku is currently Chief Medical Officer at Monte Rosa Therapeutics, Inc. since 2021.
Formerly, served as Center Medical Director & Associate Professor at The University of Texas M.D.
Anderson Cancer Center from 2012 to 2021.
Education includes a doctorate from the University of Charles.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-06-30 | 60 612 ( 0,07 % ) | 1 M $ | 2026-06-30 |
Aktiva positioner av Filip Janku
| Företag | Position | Start |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2021-06-01 |
Tidigare kända positioner av Filip Janku
| Företag | Position | Slut |
|---|---|---|
The University of Texas M.D. Anderson Cancer Center
 The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Företagsledare/Principal | 2021-05-01 |
Filip Jankus utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
37
Första gradens relationer
3
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 3 |
|---|---|
The University of Texas M.D. Anderson Cancer Center
The University of Texas M.D. Anderson Cancer Center Other Consumer ServicesConsumer Services Provides cancer patient care, research and prevention for cancer | Consumer Services |
University of Charles
 University of Charles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
